Search Bar & Filters
Found 44 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying UGN-104, a new form of UGN-101 also known as JELMYTO, to evaluate its safety and effectiveness for treating low-grade upper tract urothelial cancer LG-UTUC. This phase 3 study focuses on patients with this type of cancer located in the upper urinary tract. The research aims to understand how well UGN-104 works when placed directly into the affected area and to monitor its safety during treatment. Participants will receive UGN-104 once a week for six weeks, totaling six doses. This medication combines mitomycin with a special gel that becomes semi-solid at body temperature, allowing it to stay in the urinary tract longer. After about three months from the first dose, patients undergo evaluation to check for complete response, which includes urine tests and visual exams of the urinary tract. Those who respond completely may receive monthly maintenance doses of UGN-104 for up to 11 months. Patients who do not respond fully complete the study at this point. Throughout the study, participants will have regular clinic visits every three months for up to a year after their initial evaluation or until the cancer returns, worsens, or the patient passes away. Assessments include urine cytology, ureteroscopy, biopsies if needed, and laboratory tests to monitor mitomycin levels and side effects. Researchers will track treatment response duration, safety events, and drug concentrations to better understand the therapy and its effects over time.
Actively Recruiting
Researchers are evaluating the efficacy and safety of combining ficlatuzumab with cetuximab compared to cetuximab alone in people with recurrent or metastatic RM HPV-negative head and neck squamous cell carcinoma HNSCC. This Phase 3, randomized, double-blind, placebo-controlled study focuses on participants who have not responded to prior anti-PD-1PD-L1 immune checkpoint inhibitors and platinum-based chemotherapy. The goal is to see if adding ficlatuzumab improves survival outcomes in this patient group. Participants are assigned to one of three groups two groups receive different doses of intravenous ficlatuzumab plus cetuximab on days 1 and 15 of each 28-day cycle, while the third group receives a placebo plus cetuximab on the same schedule. The study will enroll about 410 participants and compare progression-free survival and overall survival among these groups. Treatment cycles continue until disease progression or other study endpoints. During the study, participants will undergo regular imaging scans CT or MRI to assess tumor response every 8 weeks during the first year, then every 12 weeks in years 2 and 3, and every 6 months thereafter. Researchers will monitor safety, quality of life, and immune responses, including antidrug antibodies. The study period spans approximately 44 months with ongoing evaluations from randomization until death or last response assessment.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a drug called Corabotase IPN10200 compared to a placebo for treating adults with Cervical Dystonia CD. CD causes abnormal movements and symptoms in the head and neck, such as neck pain, stiffness, and headaches. The condition may involve brain regions that control movement and could be influenced by genetic and environmental factors. This study is a Phase II trial aiming to find out if Corabotase can provide longer-lasting relief than current treatments. Participants will receive a single intramuscular injection of either Corabotase at one of three doses Dose A, Dose B, or Dose C or a placebo on Day 1 of the treatment period. The injections target muscles in the head, neck, and shoulders. The study includes two periods a Screening Period lasting up to 4 weeks to determine eligibility, followed by a 36-week Treatment Period. Participants may continue some other medications during the study, which will be recorded. During the study, participants will attend 10 in-person clinic visits and one remote visit phone call, or 12 in-person visits if receiving Dose C. They will undergo blood and urine tests, physical and neurological exams, and clinical evaluations. Participants will also fill out questionnaires throughout the study. The main outcome measured is the change in severity of CD symptoms using a specific rating scale at Week 4. Total participation lasts about 40 weeks approximately 9 months.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of KT-621, an oral drug, in adults with uncontrolled moderate to severe eosinophilic asthma. This Phase 2b trial aims to understand how well KT-621 works, how safe and tolerable it is, and how the body processes the drug. Participants will be randomly assigned to one of four groups to receive either one of three doses of KT-621 or a matching placebo. Treatment will be given orally, and the study will track changes in lung function and asthma control over 12 weeks. Safety and drug levels in the blood will be monitored through 16 weeks. Throughout the study, participants will attend scheduled visits for lung function tests, asthma symptom questionnaires, and blood tests. Researchers will measure lung function improvement, asthma control, quality of life, treatment side effects, and drug concentration in plasma. The study will last until December 2027, with assessments focused on the 12 to 16-week treatment and monitoring periods.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of lebrikizumab, a drug given by injection, in people aged 12 and older with chronic rhinosinusitis and nasal polyps who are also treated with intranasal corticosteroids. This phase 3 trial aims to improve symptoms like nasal congestion and polyp size while monitoring participant safety over about 18 months. Participants receive lebrikizumab injections on different schedules or placebo injections, all along with standard intranasal corticosteroid spray. Adolescents aged 12 to under 18 who weigh at least 40 kg are assigned to open-label lebrikizumab treatment. The study includes multiple groups receiving injections every 2, 4, or 8 weeks to compare outcomes. During the study, participants will undergo assessments including nasal congestion scoring, endoscopic evaluation of nasal polyps, sinus imaging, lung function tests, and symptom questionnaires from the start through 24 weeks. Safety and symptom changes are closely monitored, and the total study duration is approximately 18 months.
Actively Recruiting
Researchers are evaluating the pharmacokinetics, safety, and tolerability of Vaborem, a fixed combination of meropenem and vaborbactam, in children from birth up to 18 years old who have suspected or confirmed Gram negative infections requiring hospitalization and intravenous antibiotic treatment. This Phase 2 open-label study focuses on infections including complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired pneumonia, ventilator-associated pneumonia, and bloodstream infections. All participants will receive Vaborem intravenously every 8 hours for 10 to 14 days. After a minimum of 3 days of Vaborem treatment, switching to an oral antibiotic is allowed. Pharmacokinetic samples will be collected after participants have received at least six doses. This is a single-arm study where all enrolled children will get the investigational drug. During the entire hospital stay and at scheduled visits after completing treatment, participants clinical conditions will be closely monitored. Researchers will measure drug levels and clearance in the blood on Day 3 and track any treatment-emergent adverse events up to 30 days after baseline. The study aims to understand how Vaborem is processed in the body and how well it is tolerated in the pediatric population.
Actively Recruiting
Researchers are evaluating the effectiveness of glofitamab alone compared with the choice of either rituximab plus bendamustine or lenalidomide with rituximab in patients with relapsed or refractory mantle cell lymphoma. This Phase III study aims to determine which treatment better controls the disease in adults who have already received prior therapies, including a BTK inhibitor. The study involves random assignment to one of the treatment groups to compare outcomes over time. Participants assigned to the glofitamab group will receive two intravenous doses of obinutuzumab before starting intravenous glofitamab, given in 12 cycles of 21 days each. Those in the comparator group will receive either bendamustine plus rituximab for up to six 28-day cycles or rituximab plus oral lenalidomide daily for 21 days in 28-day cycles until the disease worsens. Tocilizumab may be given intravenously as needed to manage side effects related to immune response. During the study, participants will undergo regular assessments to monitor disease progression, response to treatment, physical functioning, fatigue, and lymphoma symptoms using questionnaires and clinical evaluations. Researchers will also measure drug levels and immune responses up to 24 months after randomization. Safety and effectiveness will be closely tracked, including survival and duration of response, to understand the benefits and risks of each treatment option.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of TAR-210 compared to intravesical chemotherapy in treating high-risk non-muscle-invasive bladder cancer HR-NMIBC. This Phase 3 study focuses on disease-free survival, which is the length of time participants live without signs or symptoms of cancer returning or worsening. The study targets patients with specific FGFR genetic alterations who have previously received BCG treatment but remain at high risk for cancer recurrence. Participants are randomly assigned to one of two groups Group A will have the investigational drug TAR-210 placed inside the bladder on Day 1 and continue treatment for about two years. Group B will receive intravesical chemotherapy with either mitomycin C or gemcitabine weekly for 4 to 6 doses, followed by monthly maintenance for up to one year, with an optional second year of maintenance depending on the investigators decision. All treatments are delivered directly into the bladder. Throughout the study, participants will have regular assessments including monitoring for cancer recurrence, progression, and overall survival for up to five years. Researchers will collect safety data such as adverse events and changes in laboratory tests and vital signs. Quality of life will be measured using specific questionnaires at multiple time points. The study involves ongoing visits and evaluations to closely observe treatment effects and participant well-being over the long term.
Actively Recruiting
Researchers are comparing the disease-free survival in adults with intermediate-risk non-muscle invasive bladder cancer IR-NMIBC who receive either TAR-210 or the investigators choice of intravesical chemotherapy. The study focuses on participants with susceptible FGFR alterations and aims to evaluate the efficacy and safety of these treatments over approximately four years. This is a phase 3 randomized trial sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to one of two groups. Group A receives TAR-210, which is inserted into the bladder on Day 1 and removed after 12 weeks this procedure is repeated every 12 weeks for about one year. Group B receives intravesical chemotherapy with mitomycin C MMC or gemcitabine, chosen by the investigator. Chemotherapy is given once weekly for 4 to 6 doses, followed by a maintenance phase lasting at least 6 months and up to one year. Throughout the study, participants undergo multiple cystoscopies and tissue assessments to monitor for recurrence or progression of bladder cancer. Researchers measure disease-free survival, time to next treatment, recurrence-free survival, progression-free survival, adverse events, overall survival, and quality of life using standardized questionnaires. Safety is monitored from the first dose through 30 days after the last dose. The total participation period spans about four years and two months for comprehensive evaluation.
Actively Recruiting
Researchers are studying the safety and effectiveness of a minimally invasive device called the Alleviant ALV1 System in patients with chronic heart failure, specifically those with heart failure with preserved or mildly reduced ejection fraction HFpEFHFmrEF. This prospective, multicenter, randomized, double-blind trial compares the device procedure to a sham control in order to better understand its potential benefits and risks. Participants are randomly assigned to one of two groups. Those in the treatment group undergo cardiac imaging, femoral vein access, and receive the Alleviant ALV1 System device procedure, which creates an interatrial shunt. The control group undergoes cardiac imaging and femoral vein sheath placement without the device procedure. The study has a crossover design, allowing participants to experience both conditions during the trial. During the study, participants will have cardiac imaging and exercise right heart catheterization to monitor heart function and pressures. Researchers will evaluate a composite primary endpoint at 12 months to assess safety and efficacy. Participants will be monitored for ongoing health status while continuing stable guideline-directed medical therapy. The trial is expected to complete by December 2032.
1-10 of 44
1